Nilotinib  A c-abl inhibitor used in chronic myelocytic leukemia, which seems to decrease phosphorylation of both parkin and a-synuclein  Safety and tolerability of daily oral administration of Nilotinib  Results not yet available  Ongoing (Phase 2)